|Coordinator||SAGA SURGICAL AB|
|Funding from Vinnova||SEK 998 000|
|Project duration||June 2018 - October 2019|
|Venture||Swelife and Medtech4Health- Project proposals to improve health|
|Call||Förbättrad prevention, diagnos och behandling – Swelife och Medtech4health|
Purpose and goal
Saga Surgical develops a method that will significantly reduce the risk of sepsis in the diagnosis of prostate cancer by biopsy.
Expected results and effects
First and foremost it leads to higher patient safety, but it also contributes to significantly reduced healthcare costs and decreased use of antibiotics.
Planned approach and implementation
The method will be tested on humans, first in a pilot study together with Region Skåne. The next step is to do a larger human study with more participating clinics from both Sweden and abroad. Vinnova contributes with funding for the pilot study and the preparations required to get CE-label to be approved for the larger study.